Annexure 15- Initial Review Form for Multicentric Research (Name of the Institution) EC Ref. No. (for office use):

PART 1 (To be filled by coordinating PI)

General Instructions: a) Tick one or more as applicable. Mark NA if not applicable. Attach additional sheets if required b) For submission to Designated Ethics Committee and to be shared with PIs at Participating Centres

SECTION A - BASIC INFORMATION

SECTION A - DASIC IN ORIGINATION
ADMINISTRATIVE DETAILS Name of Institute under which Designated Ethics Committee is constituted:
Name of the Ethics Committee: Name of Coordinating Principal Investigator:
Designation and Qualification:
Department/Division: (e) Date of Submission: Click here to enter a date.
Address for communication (include email and mobile no.)
Type of review requested ¹ :
Exemption from Review Expedited Review Full Committee Review
Title of the study:
Acronym/ Short title, (If any):
Protocol number (If any): Version number: Date: Click here to enter a date.
Number of studies where applicant is a:
i) Principal Investigator at time of submission: ii) Co-Investigator at time of submission
Duration of the study:
FUNDING DETAILS AND BUDGET
Total estimated budget for study:
At site In India Globally
Self-funding Institutional funding Funding agency (Specify)

¹ Refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017on Page 36 Table 4.2. for the types of review

SECTION B - RESEARCH-RELATED INFORMATION

(a)	Lay Summary of	study ² (withir	n 300 words)		
(b)	Type of study: Basic Sciences		Clinical	Cross Sectional	
	Retrospective Prospective Qualitative Quantitative		Epidemiological/ Public Health Socio-behavioural Biological	Case Control Cohort Systematic Review	
	Mixed Method		samples/Data Any others (Specify)		

4. METHODOLOGY

3. OVERVIEW OF RESEARCH

(a) Sample size/ No. of Participants (as applicable)
At site In India Globally

Control group Study Group

Justification for the sample size chosen (100 words); In case of qualitative study, mention the criteria used for selection

(b) (c)	Is there an external laborator How was the scientific quality		rinvestigation	ns?³Yes No	NA
. ,	Independent external review Review within multi-	Review by Sponsor/Funder No Review		Review within PI's institution	
	centre research group Date of review:		_	Cliab base to a	
	Date of review:			Click here to er	nter a date.

Comments of Scientific Committee, if any (100 words)

²Summarize in the simplest possible way such that a person with no prior knowledge of the subject can easily understand it.

³If participant samples are sent outside for investigations, provide details of the same and attach relevant documentation such as an MTA/ MoU etc.

SECTION C - PARTICIPANT RELATED INFORMATION

5. RECRUITMENT AND RESEARCH PARTICIPANTS

(a)	Type o Healt volun	•	nts in t	he study: Patient			nerable person/ cial groups		Others (Specify)	
	Partici	•		methods used:						
	Poste leafle	ers/ ets/Letters	Ш	TV/Radio ads/social media/Institution website	Ш		Patients / Family/Friends visiting hospitals	Ц	Telephone	Ш
	Othe	rs (Specify)					·			
(b)	i. ii.			Inerable person/spe Ilnerable person /sp	_	•	volved? Y	es 🗹	No 🗖 NA	
		Children u	ınder 1	.8 yrs.			Pregnant or lact	ating v	vomen	
		Differently	y abled	l (Mental/Physical)			Employees/Stud	dents/N	lurses/	
		Elderly					Institutionalized	I		
			/ III (sti	d socially disadvanta gmatized or rare fv):	aged		Refugees/Migra	nts/Hc	omeless	
		, canc	(0,000)	,,,,.						
	iii.	Provide ju	ıstifica	tion for inclusion/ex	clusion	l				
	iv.	Are there	any a	dditional safeguards	to prot	ect re	search participan	ts?		
(c)				nent to the participa Non-monetary		ide de	tails		Yes 🗖	No 🗖
(d)	Are the	ere any inco	entives	to the participant?					Yes 🗖	No 🗖
	If yes,	Monetary		Ion-monetary	Provid	le deta	nils			
e)	Are the	ere any par	ticipar	t recruitment fees/	incentiv	ves for	the study provid	led to t	he PI/ Institu	tion?
	If yes,	Monetary	, 	Non-monetary	Provide	e deta	ils		Yes No	

6. B	ENEFITS AND RISKS					
(a)	i. Are there any anticipated physical/social/	psycho	ological discomfo	rts/ risk t	o participants? Yes No No	
	If yes, categorize the level of risk ⁴ : Less than Minimal risk	Mir	nimal risk			
	Minor increase over minimal risk or Low Risk	□ Mo	ore than Minimal	Risk or H	igh Risk	
	ii. Describe the risk management strategy:					
(b)	What are the potential benefits from the stud	y? Y	es No If yes	s, Direc	ct Indirec	t
	For the participant					
	For the society/community					
	For improvement in science					
	Please describe how the benefits justify the ri	sks			_	
(c)	Are Adverse Events expected in the study ⁵ ?				Yes 🔲 No 🗖	NA 🗖
	Are reporting procedures and management st If Yes, Specify	rategie	es described in th	ne study?		
7. IN	NFORMED CONSENT					
(a)	Are you seeking waiver of consent? If yes, ple	ase spe	ecify reasons and	skip to q	uestion 8. Yes 🔲	No
(b)	Version number and date of Participant Information Number and date of Informed Consentations (National Number and Date of Informed Consentation)					
(c)	Type of consent planned for:					
	Signed consent		Witnessed		Audio-Video	
	consent Consent from LAR For children<7 yrs		consent Verbal assent		(A/V) consent Written Assent	
	(If so, specify from parental/LAR	_	from minor (7-		from Minor (13-	
	whom) consent		12 yrs) along with parental consent		18 yrs) along with parental consent	
	Other (specify)					
(d)	Who will obtain the informed consent? PI/Co-I Nurse/Counselor		Research Sta	off	Other (Specify)	
	Any tools to be used					

⁴For categories of risk refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017. Page 6 in Table 2.1

5 The term adverse events in this regard encompass both serious and non-serious adverse events.

(e)	English 🗖	Local	neet (PIS) and Informo language htranslations were d		sent Form (IC other 🗖	F) (specify)	
(f)			n done, please justify requirement for pre	viously	stored sampl	les if used in the study ⁶	
(g)	Elements contained	d in the	Participant Informat	ion Sh	eet (PIS) and I	nformed Consent Form (IC	CF)
	Simple language		Data/ Sample sharing		Compensati	ion for study related injury	
	Risks and discomforts		Need to recontact		Statement t	hat consent is voluntary	
	Alternatives to participation		Confidentiality		Commercial	lization/benefit sharing	
	Right to withdraw		Storage of samples		Statement t	hat study involves researc	h 🔲
	Benefits		return of research results		Use of photo	ographs/ identifying data	
	Purpose and procedure Others(Specify)	-	Payment for participation		Contact info	ormation of PI and Member FEC	er 🔲
8. P/	Who will bear the	costs i	related to participationstitution		procedures ⁷ ? onsor	Other agencies(specify)	
(b)	Is there a provisio	n for fi	ree treatment of rese	arch re	elated injuries	? Yes No	□ NA □
	If yes, then who w	vill pro	vide the treatment?			_	
(c)	Is there a provision	n for c	ompensation of resea	arch re	lated SAE? If y	yes, specify. Yes 🔲 No	□ NA□
	Sponsor 🗖 In:	stitutio	n/ Corpus funds] F	Project grants	Insurance I	
(d)	, .		r medical treatment of during the study per		•	he relatedness is determin	
(e)	Is there a provision specify.	for and	cillary care for unrela	ted illn	ess during the	e study period? If yes, plea	ase IA
⁶ Info	rmation on re-consent requi Particpants 2017, Page 54		-	al Guideli	nes for Biomedical	& Health Research Involving Human	n

⁷Enclose undertaking from PI confirming the same

9.	ST/	DRAGE AND CONFIDENTIALITY
٦.	(a)	Identifying Information: Study Involves samples/data. If Yes, Specify Yes No NA
		Anonymous/unidentified Anonymized: Irreversibly Identifiable reversibly coded coded
		If identifiers must be retained, what additional precautions will be taken to ensure that access is limited / data is safeguarded? (e.g. data stored in a cabinet, password protected computer etc.)
	(b)	Who will be maintaining the data pertaining to the study?
	(c)	Where will the data be analyzed ⁷ and by whom?
	(d)	For how long will the data be stored?
	(e)	Do you propose to use stored samples/data in future studies? If yes, explain how you might use stored material/data in the future? Yes No Maybe
		SECTION D: OTHER ISSUES
10.	PUBI	LICATION, BENEFIT SHARING AND IPR ISSUES
	(a)	Will the results of the study be reported and disseminated? If yes, specify. Yes No NA NA
	(b)	Will you inform participants about the results of the study? Yes No NA NA
	(c)	Are there any arrangements for continued provision of the intervention for participants, if effective, once the study has finished? If yes describe in brief (Max 50 words) Yes No NA
	(d)	Is there any plan for post research benefit sharing with participants? If yes, specify Yes No NA NA
	(e)	Is there is any commercial value or a plan to patent/IPR issues. If yes, Please provide details Yes No NA
	(f)	Do you have any additional information to add in support of the application, which is not included elsewhere in the form? If yes, provide the details.
	⁷ For	example, a data entry room, a protected computer etc.

SECTION E: CHECKLIST FOR COORDINATING PI

11. CHECKLIST									
S.No	Ito	ems			Yes	No	NA	Enclosure No.	EC Remarks
ADMII	NISTRATIVE REQUIREMENT	ΓS							
1.	Cover letter								
2.	Brief CV of all Investigator	S							
3.	Good Clinical Practice (Go in last 3 years	CP) training	of investig	ators					
4.	Approval of Scientific Advisory Committee/ Any		' NTF/ Ce	entral					
5.	Agreement/MTA / LOA be partners	tween colla	borating						
6.	Insurance policy/certificat	е							
7.	Evidence of external laboran externally outsourced certification								
8.	Copy of contract or ag sponsor or donor agency	the							
PROP	OSAL RELATED								
9.	Copy of the detailed proto	col							
10.	Participant Information Consent Form (ICF)(English			rmed					
11.	Assent form for minors Translated)	(12-18 yea	rs) (English	and					
12.	Proforma/Questionnaire , Interview guides/ Guid Discussions (FGDs) (Englis	des for F	ocused C	CRF)/ Group					
13.	Advertisement/material to posters etc)	o recruit pa	rticipants (1	fliers,					
PERM	ISSION FROM GOVERNING	AUTHORITI	IES						
	Other Registration/ permissions	Required	Not required	Recei	ived	Appli dd/m	ed m/yy	EC Remark	s
14.	CTRI ⁸					Enter	date		
15.	HMSC ⁹					Enter	date		
16.	Tribal Board					Enter	date		
17.	Any Other					Enter			
ANY C	THER RELEVANT INFORMA	ATION/DOC							
	Item		YES	NO	NA	Enclo no.	sure	EC remarks	
18.									

PART 2 (To be filled by S-PI at the Participating Centre)

General Instructions: a) Tick one or more as applicable. Mark NA if not applicable. Attach additional sheets if required b) For submission to Participating Ethics Committee (PEC) and to be shared with coordinating PI

SECTION A - BASIC INFORMATION

1. a) b) c) d) f)	ADMINISTRATIVE DETAILS Name of the institute under which PEC is constituted: Name of the Ethics Committee: Name of Site Principal Investigator: Designation/ Qualification: Address for communication (include mobile no. and email address):					
g)	Expected duration of the study: Estimated budget at the participating site:					
	SECTION B - RESEARCH INFORMATION					
1. a)	OVERVIEW OF RESEARCH Briefly describe the role of the participating center in the study (50-100 words):					
b)	Briefly mention local changes made in protocol, if any:					
c)	Type of review requested: Exemption from Review Expedited Review Full Committee Review					
	SECTION C – PARTICPANT RELATED INFORMATION					
1. a) b)	PATIENT RECRUITMENT AND RESEARCH PATIENTS Number of participants to be recruited at site: Site specific/ community concerns, if any					
c)	Briefly mention local changes in Recruitment/ Advocacy material:					
d)	Copy of the Local Recruitment/ Advocacy material: Yes 🔲 No 🔲					
2. a)	INFORMED CONSENT Who will obtain the informed consent? S-PI/Co-S-PI Nurse/Counselor Research Staff Other (specify) Any tools to be used					
b) c) d)	Language/s ICD is translated in: Version number and date of the Participant Informed Sheet (PIS): Version number and date of the Informed Consent form (ICF):					

e)	Copy of the Local ICD translations enclosed: Yes	No						
f)	Back translation of the ICD in English with the trans	slation c	ertific	ate Yes	No 🔲			
g)	Changes made in informed consent form (ICF), if an	ny:						
h)	Copy of the audio / visual transcript for consent en	closed,	if any:	Yes 🗖	No 🗖			
3.	DATA AND STORAGE							
i)	Brief details on data collection, storage, sharing, transfer, if any?							
	SECTION D – OTHER ISSUES							
a)	Do you have any additional information to add	in suppo	_	the app				
	elsewhere in the form? If yes, provide the detai	ls.			Yes 📙	No 🔲		
	SECTION E – CHECKLIST FOR S-PI A	Γ ΡΔΒΊ	TICP/	ATING	CENTER			
. CHEC			11017	***************************************	CLIVILIN			
Sr.No	Items	Yes	No	NA	EnclosureNo.	EC Remarks		
ADMINI	STRATIVE REQUIREMENTS				T			
1.	Cover letter							
2.	Brief CV of Site Principal Investigator / other site Co-PI							
3.	Good Clinical Practice (GCP) training of investigator in last 3 years							
4.	Agreement between collaborating partners							
5.	MTA between collaborating partners							
6.	Insurance policy/certificate							
ROPOS	SAL RELATED							
7.	Copy of the modified protocol							
	, ,							
8.	Participant Information Sheet (PIS) and Informed Consent Form (ICF) (English and translated)							
9.	Participant Information Sheet (PIS) and Informed Consent Form (ICF) (English and translated) Assent form for minors (12-18 years) (English and Translated)							
	Participant Information Sheet (PIS) and Informed Consent Form (ICF) (English and translated) Assent form for minors (12-18 years) (English and							
9.	Participant Information Sheet (PIS) and Informed Consent Form (ICF) (English and translated) Assent form for minors (12-18 years) (English and Translated) Proforma/Questionnaire / Case Report Forms (CRF)/ Interview guides/ Guides for Focused							